(Q42978398)

English

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin

scientific article published on May 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Mindie H Nguyen

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Huy N Trinh

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ruel Garcia

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gloria Nguyen

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Khoa D Lam

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Emmet B Keeffe

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1131-1135

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Complete coding sequence of hepatitis C virus genotype 6a.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Proteinase activated receptor 2: a protean effector comes of age.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Chronic hepatitis C: genotypes 4 to 9.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Introduction to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Treatment of acute hepatitis C with interferon alfa-2b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Hepatitis C: does race really matter?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Treatment of patients with hepatitis C and normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01793.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2008.01793.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42978398&oldid=1975610534"